bear the docket control number ATSDR–214. This material is available for public inspection at the Division of Toxicology and Environmental Medicine, Agency for Toxic Substances and Disease Registry, 4700 Buford Highway, Building 106, Second Floor, Chamblee, Georgia 30341 between 8 a.m. and 4:30 p.m., Monday through Friday, except legal holidays.

Availability

This notice announces the availability of the final toxicological profile for perchlorates, which completes the nineteenth set prepared by ATSDR. The following toxicological profile is now available at *http://www.atsdr.cdc.gov/toxpro2.html* or through the U.S. Department of Commerce, National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, telephone 1–800–553–6847. This profile is available for a fee as determined by NTIS.

Toxicological profile	NTIS Order No.	CAS No.
Perchlorates	PB2009–100006.	10034–81–8 007778–81–8 007790–74–7 007601–89–0 007791–03–9

Dated: October 9, 2008.

Ken Rose,

Director, Office of Policy Planning and Evaluation, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry.

[FR Doc. E8–24388 Filed 10–14–08; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92–463) of October 6, 1972, that the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel, Department of Health and Human Services, has been renewed for a 2-year period through September 18, 2010.

For information, contact Elaine Baker, Executive Secretary, Disease, Disability, and Injury Prevention and Control Special Emphasis Panel, Department of Health and Human Services, 57 Executive Park Drive, 4th Floor, Mailstop E72, Atlanta, Georgia 30329, telephone (770) 498–0090; fax (770) 498–0011.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: October 8, 2008.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E8–24409 Filed 10–14–08; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee:

Times and Dates: 12:30 p.m.–5 p.m., October 29, 2008. 8:30 a.m.–5 p.m., October 30, 2008.

Place: The Westin San Diego, 400 West Broadway, San Diego, California 92101, Telephone: (619) 338–3613, Fax: (619) 239–4527.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 125 people.

Purpose: The committee provides advice and guidance to the Secretary; the Assistant Secretary for Health; and the CDC Director regarding new scientific knowledge and technologic developments and their practical implications for childhood lead poisoning prevention efforts. The committee also reviews and reports regularly on childhood lead poisoning prevention practices and recommends improvements in national childhood lead poisoning prevention efforts.

Matters to be Discussed: Agenda items are subject to change as priorities dictate; however, the current agenda includes

- Discussion on the potential approaches to strengthen existing strategies to achieve the Healthy People 2010 goal of eliminating elevated blood lead levels (BLLs) as a public health problem in the United States by 2010;
- Update on school performance and concurrent BLLs;
- Discussion on study designs related to adverse effects from BLLs <10 μg/dL; and
- Discussion on the development of a prevention-based research agenda.

Opportunities will be provided during the meeting for oral comments. Depending on the time available and the number of requests, it may be necessary to limit the time for each presenter.

FOR FURTHER INFORMATION CONTACT: Claudine Johnson, Program Operations Assistant, Telephone: (770) 488–3629; Barry Brooks, Administrative Team Leader, Telephone: 770–488–3841; Lead Poisoning Prevention Branch, Division of Environmental Emergency Health Services, National Center for Environmental Health, CDC, 4770 Buford Hwy., NE., Mailstop F60, Atlanta, Georgia 30341.

(The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.)

Dated: October 7, 2008.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E8–24394 Filed 10–14–08; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee to the Director, Centers for Disease Control and Prevention (CDC)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the CDC announces the following meeting of the aforementioned committee:

Time and Date: 8 a.m.–3:30 p.m., October 30, 2008.

Place: CDC, Tom Harkin Global Communications Center, Auditorium B, 1600 Clifton Road, NE., Atlanta, GA 30333.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 150 people.

Purpose: The committee will provide advice to the CDC Director on strategic and other broad issues facing CDC.

Matters To Be Discussed: Agenda items will include discussions on budget challenges for Fiscal Year 2009 and beyond;

reports from the Ethics Subcommittee and National Biosurveillance Advisory Subcommittee; progress report on Healthiest Nation; and discussions on globalization. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Brad Perkins, M.D., M.B.A., Executive Officer, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE., M/S D–14, Atlanta, Georgia 30333. Telephone 404/639–7000.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the CDC and the Agency for Toxic Substances and Disease Registry.

Dated: October 8, 2008.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E8–24499 Filed 10–14–08; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2008–N–0523]

FDA–Regulated Products that Contain Bisphenol-A; Request for Information

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for information.

SUMMARY: The Food and Drug Administration (FDA) is requesting assistance in the identification of types of FDA-regulated products that contain Bisphenol A (BPA), whether as a component of the product or its packaging, and any information relating to the leaching of BPA from the packaging to the product and/or from the product from the product following human administration.

DATES: Submit written or electronic comments and information by December 29, 2008.

ADDRESSES: Submit written comments and information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments and information to *http://www.regulations.gov*. Information submitted will be reviewed by the FDA BPA Task Force.

FOR FURTHER INFORMATION CONTACT: Norris Alderson, Office of Science and Health Coordination (HF–32), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3340, FAX 301–827–3042, e-mail: norris.alderson@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

BPA is a chemical commodity used primarily in the production of polycarbonate plastics and epoxy resins. Such plastics and resins have many applications including as components of packaging for food and drink, and as components of certain medical products and their packaging. Consequently, low levels of residual BPA may be present in such products. On April 14, 2008, the National Toxicology Program (NTP) released a draft brief on BPA for public comment and peer review. The NTP draft brief raises concerns that exposure to BPA could be linked to developmental problems of the endocrine system in infants and young children. The NTP draft brief also contains an exposure estimate to BPA for infants and young children due to leaching of BPA to food from plastic baby bottles and the linings of certain baby food containers. NTP has subsequently released a final report on BPA on September 3, 2008.

In response to the NTP draft brief, Commissioner von Eschenbach has convened an agency-wide task force to facilitate cross-agency review of current research and new information on BPA for all FDA-regulated products. The review will include the NTP brief and all other available information on the exposure of US consumers to BPA from FDA-regulated products.

During the course of this process the task force has been making an inventory of all FDA-regulated products that are known to contain BPA. The task force has already completed a thorough assessment of the potential exposure to BPA due to leaching from food-contact materials and is now interested in additional information on other types of products, specifically medical devices, biological products (including blood, blood products, vaccines, and cell and gene therapies, and drugs.

To ensure that we have current information to support our review of issues related to BPA risks, we are requesting information on the presence and levels of BPA for products with either direct or indirect patient contact. This would include situations where the BPA is a component of the product or its packaging. Information relating to the leaching of BPA from the packaging to the product and/or from the product to patients is also of interest.

At this time, exposure to BPA from the use of the following BPA-related materials provides an initial basis for the agency's query:

- Polycarbonate.
- Polyether sulfone.
- Polycarbonate/siloxane co-polymer.
- Biostable polyurethanes.
- Epoxy resin.

The agency's query also extends to products that contain certain bisphenol acrylic oligomers, such as the following:

- Bisphenol A diglycidylether methacrylate (BIS-GMA).
- Bisphenol A diglycidylether (BADGE).
- Bisphenol A dimethacrylate (BIS-DMA).
- Ethoxylated bisphenol A diacrylates.

II. Information Requested for FDA-Regulated Products

A. Medical Devices and Articles Used in Product Manufacturing

Direct contact devices would include, but not be limited to, those with direct contact with tissue, blood, other fluids, such as cerebrospinal fluid, and skin. Implants, catheters, and most dental devices are additional examples of devices with direct patient contact.

Indirect patient contact or external communicating devices would include, but are not limited to the following:

- Components of blood pathway circuits, (e.g., hemodialysis, apheresis, and cardiopulmonary bypass).
- Respiratory tubing circuits.
- Blood and parenteral solution administration sets.
- Apheresis instrument harnesses including separation bowls and break away closures.
- Hard casing for leukocyte reduction filters.
- Platelet rich plasma preparation devices including tubes for centrifugation of blood.
- Tops for vials or other container closures.
- Large volume containers used in preparation of raw materials for biological products production when lined with epoxy material that contains BPA.
- Materials used for preparation of cell/tissue/gene therapies, including: T-flasks, roller bottles, cell factories, cell culture beads, hard conical tubes, and disposable plastic pipettes.

In submitting your comments, we ask you to provide information with respect to any Class I, Class II, and Class III medical device that has direct or indirect patient contact. Whenever possible, include a description of the analytical method used to develop the submitted data and information.

If the device contains polycarbonate or BPA, we request the submission of data concerning the following: